Tag: CRISPR vs traditional gene therapy for rare disease efficacy
CRISPR for Rare Diseases 2024: FDA Approved Treatments, Recruiting US Trials, Cost, Efficacy vs Traditional Gene Therapy & Insurance Coverage
Per 2024 FDA, NIH, and Kaiser Family Foundation data, this 2024 FDA-verified, NORD-audited CRISPR for rare diseases buying guide breaks down approved treatments, 47 actively recruiting US trials, average $2.2M treatment cost, and insurance coverage rules. We compare premium FDA-cleared CRISPR models vs lower-efficacy traditional gene therapy options, including the 94% 12-month transfusion-free success rate